11α-methyl-11β-hydroxyprogesterone | 14418-07-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 11α-methyl-11β-hydroxyprogesterone
• 英文别名: (8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-10,11,13-trimethyl-1,2,6,7,8,9,10,11, 12,13, 14, 15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthrene-3-one；11α-Methyl-11β-hydroxy-Δ⁴-pregnendion-(3,20)；11β-hydroxy-11α-methyl-pregn-4-ene-3,20-dione；11β-Hydroxy-11α-methyl-pregn-4-en-3,20-dion；(8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-10,11,13-trimethyl-2,6,7,8,9,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 14418-07-6
• 化学式: C₂₂H₃₂O₃
• 分子量: 344.494
• InChiKey: OICJFNXMZMDAEH-VUIPWDCGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  11α-methyl-11β-hydroxyprogesterone 生成 11α-Methyl-6ξ,7ξ,11β-trihydroxypregna-1,4-dien-3,20-dion
  参考文献：
  名称：

  研究A-norsteroids-VI：作为C指导作用11上添加四氧化锇对甾族Δ的-取代基的1,4- -3-酮

  摘要：

  C的影响11 -取代基上Δ的羟基化1,4- -3- oxosteroids用四氧化锇，已经被检查。在11α-取代基，如11α羟基，1α乙酰氧基或11α甲基11β-羟基，导致在Δ选择性加成的四氧化锇4双键，给人4β，5β二羟基Δ 1 -3 -氧类固醇。在另一方面中，11-氧代产量只1α，2α二羟基Δ 4 -3- oxosteroids。

  DOI：

  10.1016/0040-4020(67)85047-6
• 作为产物：
  描述：

  4ξ-chloro-11β-hydroxy-11α-methyl-5β-pregnane-3,20-dione 在 盐酸氨基脲 、 sodium acetate 、 N,N-二甲基甲酰胺 作用下， 生成 11α-methyl-11β-hydroxyprogesterone
  参考文献：
  名称：

  Notes: 11-Alkylated Steroids. III. Two Syntheses of 11-Methylhydrocortisone

  摘要：

  DOI：

  10.1021/jo01092a627

文献信息

• NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION
  申请人：SPHAERA PHARMA PVTD. LTD.

  公开号：US20150376225A1

  公开（公告）日：2015-12-31

  The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

  本发明提供了11β-羟基类固醇的新化合物、组合物及其作为药物的应用，用于预防或逆转线粒体损伤，治疗或预防与线粒体功能失调或耗竭有关的疾病，并诱导线粒体再生或重构作为治疗人或动物主体中线粒体结构和功能异常相关疾病的手段。本文还公开了诊断线粒体损伤和诊断治疗、预防或逆转线粒体损伤或耗竭的治疗剂成功或失败的方法。
• 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION
  申请人：Sphaera Pharma Pvt. Ltd.

  公开号：EP3309166A2

  公开（公告）日：2018-04-18

  The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

  本发明提供了11β-羟基类固醇的新型化合物和组合物及其作为药物的应用，用于预防或逆转对线粒体的损伤，治疗或预防与线粒体功能障碍或耗竭有关的疾病，以及诱导线粒体的再生或重组，作为治疗与人或动物体内线粒体结构和功能异常有关的疾病的一种手段。本文还公开了诊断线粒体损伤和诊断旨在治疗、预防或逆转线粒体损伤或耗竭的疗法成败的方法。
• [EN] NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION<br/>[FR] NOUVEAUX COMPOSÉS DE 11BÊTA-HYDROXY-STÉROÏDES DESTINÉS À ÊTRE UTILISÉS UTILISATION DANS LA BIOGENÈSE DE MITOCHONDRIES ET LES MALADIES ASSOCIÉES AVEC LA DYSFONCTION OU LA DÉPLÉTION MITOCHONDRIALE
  申请人：SPHAERA PHARMA PRIVATE LTD

  公开号：WO2014115167A2

  公开（公告）日：2014-07-31

  The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.